Kolexia
Pica Gian Matteo Hématologie
Pica Gian Matteo
Hématologie
Hôpital Chambéry
Chambéry, France
40 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome folliculaire Neutropénie Maladies de la peau Lymphome malin non hodgkinien Leucémies Hémophilie A Lymphome T Lymphome B

Collaborateurs

Voir plus
Faurie Pierre
Faurie Pierre
Hôpital Chambéry, Chambéry, France
Meyer Pascal
Meyer Pascal
Hôpital Chambéry, Chambéry, France
Hacini Maya
Hacini Maya
Hôpital Chambéry, Chambéry, France
Dony Arthur
Dony Arthur
Hôpital Chambéry, Chambéry, France

Industries

Voir plus
Janssen
15 collaboration(s)
Dernière en 2023
Sanofi
6 collaboration(s)
Dernière en 2023
Abbvie
5 collaboration(s)
Dernière en 2023
Amgen
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
AGORA-1 /ALFA 2100 Study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML
Essai Clinique (Centre Antoine Lacassagne)   09 novembre 2023
RELEVANCE: A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Essai Clinique (Celgene)   10 août 2023
ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA: FINAL ANALYSIS OF THE RO-CHOP TRIAL
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Quality of life and response shift effect of diffuse large B-cell lymphoma French patients included in prospective real-life REALYSA cohort in the first year after diagnosis
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study.
2022 ASCO Annual Meeting I   02 juin 2022
PONAZA: OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS - PONAZA TRIAL
Essai Clinique (Centre hospitalier de Versailles)   06 août 2020
HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY
15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18–22 June, 2019   12 juin 2019
RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY
15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18–22 June, 2019   12 juin 2019
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
The New England journal of medicine   01 octobre 2018